3 research outputs found
Semantic enrichment and exploration process on domain specific digital libraries
No full textWith the growing number of scientific publications, the conceptof navigating effectively and searching for domain specific informationis rather significant and highly important for the scientificcommunity [2]. For instance, to search by topics, research methods,used datasets, or scientific objectives. Such deep meta-data increaseour perception for a given domain (i.e. Data Processing Pipelines) andfacilitate us to understand and visualize the evolution of researchtopics and venues over time. Nevertheless, the extraction of suchdeep meta-data from text-based documents is notorious challengingand demanding due to the unstructured and ambiguous languageof the text in different publications.The work in this paper has already contributed into two publicationattempts; with one published paper at ESWC conference,and one accepted paper at the TPDL conference. Furthermore, thework in this project extends the analysis of previous attempts byadding more data from the domain of Data Processing Pipelines andby including one additional domain for analysis (i.e. the domainof Robotics). Moreover, this work provides justifications for all theimplementation decisions and proposes a refined version of theonline domain-aware semantic enrichment framework (SmartPub),that automates the generation of deep meta-data by utilizing keyfacets from the domains of Data Processing Pipelines and Robotics.The goal is to generate structured meta-data (i.e. named entities orphrases), from full-text scientific publications, with respect to a setof domain aware facets (i.e. Objective, Methods, Dataset, Software,and Results), and afterwards, to construct groups of facet-terms (i.e.facet-topics) according to their semantic similarity for allowingdata exploration and navigation. Finally, the proposed frameworkis evaluated both quantitatively and qualitatively on seventeen conferenceseries from the domains of Data Processing Pipelines andRobotics.<br/
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
No full textBackground GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
